| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Endocrine therapy (androgen ablation) is the main treatment for advanced prostate cancer. Despite an initial efficacy of androgen deprivation therapy, prostate cancer progress within a few years from androgen-dependent to castration- resistant (CRPC) disease in most of the patients. Although AR still plays an essential role in CRPC, AR inhibitor is only an antagonist.
We hypothesized that a new type AR inhibitor could serve as a unique therapeutic agent for prostate cancer. To identify a new type AR inhibitor, we screened cultured broths of microorganisms and found that small molecule compound N-deoxynortryptoquivaline (DNT), a novel inhibitor of AR function, showed potent inhibition against androgen-dependent proliferation of LNCaP prostate cancer cells. DNT showed significant inhibition of AR nuclear translocation and against androgen-dependent proliferation of LNCaP cells.
|
